April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
A Novel Class of Hydrazones Confers Nonhypoxic Activation of HIFα by Potent Inhibition of Proline Hydroxylation
Author Affiliations & Notes
  • George Hoppe
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • Joseph Potter
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • Jonathan E. Sears
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  George Hoppe, None; Joseph Potter, None; Jonathan E. Sears, None
  • Footnotes
    Support  Research to Prevent Blindness Challenge Grant, Cleveland Clinic Product Development Fund, Knights Templar Eye Foundation.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3989. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      George Hoppe, Joseph Potter, Jonathan E. Sears; A Novel Class of Hydrazones Confers Nonhypoxic Activation of HIFα by Potent Inhibition of Proline Hydroxylation. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3989.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Hypoxia inducible factor (HIF) prolyl hydroxylase (PHD) inhibition stabilizes the catabolism of HIF, thereby exerting pleiotropic effects on hematopoiesis and vascular integrity including prevention of oxygen induced retinopathy. We have recently discovered a novel class of hydrazones that are extremely potent activators of HIF. In this study we set out to determine whether these compounds act as hypoxia mimetics, i.e., control HIF hydroxylation and stability.

Methods: : 25 compounds were selected from a Chembridge, LOPAC and NPL chemical libraries using a screening strategy that employed a hypoxia response element fused to the luciferase reporter gene. High, medium, and low inducers of luminescence were chosen to be further tested in hepatocytes and Müller cells for their effects on VEGF and erythropoietin (Epo) secretion, and HIF-1α hydroxylation. Anti-HIF-1α antibody was used to probe Müller (MIO-M1) and Hep3B lysates by Western blot. VEGF and Epo ELISA tested secretion of the proteins into MIO-M1 and Hep3B media. Anti-hydroxy-HIF-1α (Pro564) antibody was used in Western blot to determine whether these compounds inhibited HIF PHD after administration of a proteasome inhibitor MG132.

Results: : Submicromolar concentrations of various hydrazone molecules induced robust accumulation of HIF-1α and HIF-2α proteins. These increases correlated to both VEGF and Epo secretion in a hierarchal manner although compound D5 induced both VEGF and Epo to a greater extent in Hep3B cells than in MIO-M1 cells, whereas compound D1 was more active in the latter. Cultured Müller cells did not produce Epo. All compounds efficiently prevented hydroxylation of HIF-1α Pro564, the degree of which correlated to the expression levels of HIF downsteam targets.

Conclusions: : This new class of compounds stabilizes HIF-1α and 2α with associated increases in Epo and VEGF, two of which were cell type specific. In addition, these compounds prevent α subunit hydroxylation, and therefore are direct inhibitors of HIF PHD with a potential for neurovascular protection and repair in retinal ischemic disease.

Keywords: retinopathy of prematurity • transcription factors • hypoxia 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.